-
炎性肌纤维母细胞瘤(inflammatory myofibroblastic tumor,IMT)是一种少见的具有复发潜能的间叶源性肿瘤,病理组织学上是由一种主要由分化的肌纤维母细胞性梭形细胞组成、常伴有大量浆细胞和(或)淋巴细胞的少见肿瘤[1]。肌纤维母细胞瘤的良恶性是一个具有争议的问题,目前认为肌纤维母细胞瘤为良性病变,仅有少数多灶性肌纤维母细胞瘤易于多处复发,甚至转移[2]。笔者分析1例临床确诊为恶性肌纤维母细胞瘤的18F-FDG PET/CT影像学表现及鉴别诊断,旨在提高对该病的认识。
18F-FDG PET/CT炎症性肌纤维母细胞瘤恶变一例
Malignant inflammatory myofibroblastoma: 18F-FDG PET/CT imaging
-
摘要: 笔者报道了一例炎症性肌纤维母细胞瘤恶变病例,从临床症状、CT、18F-FDG PET/CT检查、临床诊断、病理诊断及预后等方面介绍并分析该病特点,并通过文献复习加深了对炎症性肌纤维母细胞瘤的认识。该病例为炎症性肌纤维母细胞瘤恶变,疾病进展快,影像学表现无特异性,通过病理及预后诊断。肌纤维母细胞瘤一般以良性为主,恶性发病率少,一旦发生,容易误诊,需结合临床、影像学检查、病理结果、治疗效果及预后综合考虑。Abstract: A case of malignant inflammatory myofibroblastoma was reported. The characteristics of the disease were analyzed using clinical symptoms, CT, 18F-FDG PET/CT examination, clinical diagnosis, pathological diagnosis, and prognosis. The understanding of this disease was deepened through literature review. The case was verified as malignant inflammatory myofibroblastoma. The disease progresses quickly and had low specificity. Diagnosis needed pathology and prognosis. Myofibroblastoma is mostly benign, and the incidence of malignant diseases is small. Once myofibroblastoma occurs, it is easy to misdiagnose. Thus, a combination of clinical, imaging, pathological, therapeutic, and prognostic considerations is needed.
-
Key words:
-
[1] Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now?[J]. J Clin Pathol, 2008, 61(4): 428−437. DOI: 10.1136/jcp.2007.049387. [2] 谢军伟, 毛宇强, 赵振坤, 等. 复发性胸壁来源炎性肌纤维母细胞瘤一例[J/OL]. 中华肺部疾病杂志(电子版), 2019, 12(3): 390−391 [2019−01−01]. http://zhfbjbzz.yiigle.com/CN119295201903/1151632.jhtml. DOI: 10.3877/cma.j.issn.1674−6902.2019.03.033.
Xie JW, Mao YQ, Zhao ZK, et al. One case of recurrent chest wall inflammatory fibroblastoma[J/OL]. Chin J Lung Dis (Electron Ed), 2019, 12(3): 390−391 [2019−01−01]. http://zhfbjbzz.yiigle.com/CN119295201903/1151632.jhtml. DOI: 10.3877/cma.j.issn.1674−6902.2019.03.033.[3] Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases[J]. Am J Surg Pathol, 2007, 31(4): 509−520. DOI: 10.1097/01.pas.0000213393.57322.c7. [4] 陈亚男, 杨智明, 王甜, 等. 炎性肌纤维母细胞瘤的影像及病理对照分析[J]. 放射学实践, 2018, 33(3): 294−298. DOI: 10.13609/j.cnki.1000−0313.2018.03.014.
Chen YN, Yang ZM, Wang T, et al. Imaging characteristics of inflammatory myofibroblastic tumor and correlation with pathology[J]. Radiol Pract, 2018, 33(3): 294−298. DOI: 10.13609/j.cnki.1000−0313.2018.03.014.[5] Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor[J]. Genes, Chromosomes Cancer, 2002, 34(4): 354−362. DOI: 10.1002/gcc.10033. [6] Tsuzuki T, Magi-Galluzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder[J]. Am J Surg Pathol, 2004, 28(12): 1609−1614. DOI: 10.1097/00000478−200412000−00009. [7] 荆轶群, 谭红娜. 炎性肌纤维母细胞瘤的临床病理及CT特征分析[J]. 临床放射学杂志, 2018, 37(3): 481−485. DOI: 10.13437/j.cnki.jcr.2018.03.031.
Jing YQ, Tan HN. Clinicopathologic and CT Findings of Inflammatory Myofibroblastic Tumor[J]. J Clin Radiol, 2018, 37(3): 481−485. DOI: 10.13437/j.cnki.jcr.2018.03.031.[8] 林铸, 胡婉明, 李永红, 等. 外科治疗泌尿生殖系统炎性肌纤维母细胞瘤15例临床分析[J]. 中华医学杂志, 2019, 99(12): 947−949. DOI: 10.3760/cma.j.issn.0376−2491.2019.12.014.
Lin Z, Hu WM, Li YH, et al. Surgical treatment for inflammatory myofibroblastic tumor in genito-urinary system: a study of 15 cases[J]. Natl Med J China, 2019, 99(12): 947−949. DOI: 10.3760/cma.j.issn.0376−2491.2019.12.014.